Navigation Links
Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
Date:8/27/2012

LAUSANNE, Switzerland, August 27, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

The multicentre, open-label, non-randomised study will involve 44 children from the United States, Chile and Mexico. Its primary objective is to evaluate the efficacy and safety of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in decreasing luteinizing hormone (LH) to prepubertal levels at Month 6 (Day 169) in children with CPP.

"We are excited to be part of this study, which is the first Debiopharm-sponsored clinical trial using triptorelin for the treatment of CPP," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group. "Our aim is to show that a gonadotropin-releasing hormone (GnRH) agonist therapy prevents the social and psychological difficulties associated with premature sexual development, and has a positive impact on compromised adult height. The 6-month-formulation would entail an improved compliance in a paediatric indication for which no other 6-month GnRH agonist formulation is currently approved, whilst reducing the frequency of injections in children."

About Central Precocious Puberty (CPP)

GnRH-dependent CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys. It is characterised by early pubertal changes such as breast development and start of menses in girls and increased testicular and penile growth in boys, appearance of pubic hair, as well as acceleration of growth velocity and bone maturati
'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
2. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
3. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
4. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
5. Response Genetics, Inc. Announces Second Quarter Financial Results
6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
7. Westpak Announces New Cold Chain Test Division
8. Yongye International Announces Second Quarter 2012 Financial Results
9. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
10. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
11. BioMed Realty Announces New Brand Identity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Jan. 3 Escalon Medical Corp.,(Nasdaq Capital Market: ... 510(k) clearance from the U.S. Food and Drug,Administration ... The MASTER-VU(TM) System consists of a B-scan probe ... (via a USB cable,connection) using Sonomed,s proprietary software, ...
... Jan. 3 Cinpathogen, through its,partnership in the ... clinical diagnostic technology consulting,services to Shanghai area hospitals. ... the,Shanghai Health Study, the Center has diagnosed and ... in collaboration with area,hospitals and colleagues at Fudan ...
... KENILWORTH, N.J., Jan. 2 Schering-Plough,Corporation (NYSE: ... and Drug,Administration (FDA) has assigned priority review status ... Sugammadex is specifically designed to reverse the ... States as ZEMURON(R) (rocuronium,bromide) and vecuronium bromide. Muscle ...
Cached Biology Technology:Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 2Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... today in the journal Genome,Research that they have ... a 554-kilobase-pair genomic,segment near the centromere of the ... genes that could be implicated in,sex-associated height differences ... one of the few holes remaining in the,"finished" ...
... in comparison to the 3.2 gigabases of its human ... 14 proteins, which play different roles in promoting viral ... host’s cellular machinery—including RNA polymerases, which carry out transcription—to ... chromosomal DNA. Once the virus is integrated (now called ...
Cached Biology News:NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Novel Enzyme Shows Potential As An Anti-HIV Target 2Novel Enzyme Shows Potential As An Anti-HIV Target 3